Market Place
Sourcing Support
Tourmaline Bio Announces Closing of Merger with Talaris Therapeutics
19 Oct 2023 //
GLOBENEWSWIRE
Talaris Therapeutics Announces Stockholder Approval of Merger with Tourmaline
17 Oct 2023 //
GLOBENEWSWIRE
Talaris CGT plants bulk out NYBCe CDMO biz
06 Oct 2023 //
BIOPROCESS INTERNATIONAL
Talaris Declares Dividend In Connection with Proposed Merger with Tourmaline
06 Oct 2023 //
GLOBENEWSWIRE
Talaris Therapeutics to merge with Tourmaline Bio
23 Jun 2023 //
PHARMACEUTICAL TECHNOLOGY
Talaris reverse merger tees up midphase trials of ex-Pfizer drug
22 Jun 2023 //
FIERCE BIOTECH
Tourmaline Bio reverse merges into Talaris and raises funds
22 Jun 2023 //
ENDPTS
Talaris Therapeutics Announces Leadership Transition
26 May 2023 //
GLOBENEWSWIRE
Talaris lays off 95% of workforce after fruitless deal hunt
18 Apr 2023 //
FIERCE BIOTECH
Talaris discontinues trials, cuts staff, starts ‘strategic alternatives’ search
17 Feb 2023 //
ENDPTS
Talaris Announces Plans to Explore Alternatives & Implements Restructuring Plan
16 Feb 2023 //
GLOBENEWSWIRE
Talaris ends recently restarted kidney transplant studies
16 Feb 2023 //
FIERCE BIOTECH
Talaris to Participate at the 5th Annual Evercore ISI HealthCONx Conference
22 Nov 2022 //
GLOBENEWSWIRE
Talaris Therapeutics Announces 3Q Financial Results and Corporate Update
10 Nov 2022 //
GLOBENEWSWIRE
Talaris Therapeutics Presents Data on Mechanisms of FCR001 Activity
07 Nov 2022 //
GLOBENEWSWIRE
Talaris restarts trial after assurance regarding patient death
21 Oct 2022 //
FIERCEBIOTECH
Talaris Therapeutics Provides Update on FREEDOM-1 Phase 3 Clinical Trial
20 Oct 2022 //
GLOBENEWSWIRE
Talaris Therapeutics to Present at the 2022 Cell & Gene Meeting on the Mesa
04 Oct 2022 //
GLOBENEWSWIRE
Talaris Therapeutics to Present at William Blair’s Innovations in Solid Organ
21 Sep 2022 //
GLOBENEWSWIRE
Talaris Therapeutics Announces Second Quarter Financial Results
15 Aug 2022 //
GLOBENEWSWIRE
Talaris Therapeutics Provides FREEDOM-1 Phase 3 Clinical Update
30 Jun 2022 //
GLOBENEWSWIRE
Talaris Tx Presents Additional PII Data and Analyses at American Transplant Congress 2022
07 Jun 2022 //
PRESS RELEASE
Talaris Therapeutics Announces Conference Call to Highlight Presentations at ATC
01 Jun 2022 //
GLOBENEWSWIRE
Talaris Therapeutics to Present at the Jefferies Healthcare Conference
31 May 2022 //
GLOBENEWSWIRE
Talaris Therapeutics Announces Changes to Board of Directors
17 May 2022 //
GLOBENEWSWIRE
Talaris Therapeutics to Present at the H.C. Wainwright Conference
17 May 2022 //
GLOBENEWSWIRE
Talaris Therapeutics Announces First Quarter Financial Results
12 May 2022 //
GLOBENEWSWIRE
Talaris Announces Upcoming Presentations at American Transplant Congress
02 May 2022 //
GLOBENEWSWIRE
Talaris Tx Presents Data on COVID-19 Outcomes Among Kidney Transplant Patients
06 Apr 2022 //
GLOBENEWSWIRE
Talaris Therapeutics to Participate at Two Upcoming Investor Conferences
22 Mar 2022 //
GLOBENEWSWIRE
Talaris Tx says Q4 and Year-End Financial Results
17 Mar 2022 //
GLOBENEWSWIRE
Talaris to Present at the H.C. Wainwright BioConnect 2022 Virtual Conference
04 Jan 2022 //
GLOBENEWSWIRE
Talaris Therapeutics Announces Addition to the Nasdaq Biotechnology Index
20 Dec 2021 //
GLOBENEWSWIRE
Talaris Therapeutics Presents High-Resolution Analysis of HLA
14 Dec 2021 //
GLOBENEWSWIRE
Talaris Announces Q3 2021 Financial Results and Provides Business Update
12 Nov 2021 //
GLOBENEWSWIRE
Talaris Provides Phase 3 Clinical Update and Presents Phase 2 Data and Analyses
04 Nov 2021 //
GLOBENEWSWIRE
Talaris begins Phase II clinical trial of allogeneic cell therapy
01 Nov 2021 //
CLINICALTRIALSARENA
Talaris Therapeutics Announces Initiation of Phase 2 Clinical Trial of FCR001
29 Oct 2021 //
GLOBENEWSWIRE
Talaris Therapeutics Announces Upcoming Presentations and Investor Conference
28 Oct 2021 //
GLOBENEWSWIRE
Talaris Announces Upcoming Presentations on FCR001 at the Virtual 2021
03 Jun 2021 //
GLOBENEWSWIRE
Talaris Therapeutics Announces Pricing of Initial Public Offering
06 May 2021 //
GLOBENEWSWIRE
Gyroscope and Talaris set IPO terms
03 May 2021 //
ENDPTS
Talaris Therapeutics Appoints Four Vice Presidents in Areas of Strategic
24 Feb 2021 //
BUSINESSWIRE
Talaris Therapeutics bags another $115M to curb immunosuppression in organ
07 Oct 2020 //
ENDPTS
Talaris Therapeutics bags another $115M
06 Oct 2020 //
ENDPTS
Talaris Therapeutics Closes $115 Million Series B Financing
06 Oct 2020 //
BIOSPACE
Talaris Announces First Patient Dosed in Ph 3 Clinical Trial of FCR001
22 Jul 2020 //
BUSINESSWIRE
Talaris Announces First Patient Dosed in Phase 3 Clinical Trial of FCR001
21 Jul 2020 //
BUSINESSWIRE
Update on Talaris’ Ph2 Study of FCR001 in Living Donor Kidney Recipients
29 May 2020 //
BUSINESSWIRE
